Try our Advanced Search for more refined results

Federal Trade Commission v. Illumina Inc. et al

  1. July 21, 2021

    Illumina 'Wasting Court Time' With Deal Overtures, FTC Says

    Federal Trade Commission staffers contesting biotech giant Illumina's planned $8 billion purchase of cancer detection company Grail assailed the companies Tuesday for seeking a settlement conference in the in-agency challenge process, arguing the firms aren't sincere and are really just trying to get an advanced peak at FTC tactics.

  2. June 01, 2021

    FTC's Illumina-Grail Court Case Dropped Despite Cos.' Protest

    A California federal judge has let the Federal Trade Commission drop its federal court challenge to biotech giant Illumina's planned purchase of a cancer detection company but kept the door open to a future suit, despite the firms' warning that doing so would let the commission kill the deal later by reviving its challenge as the merger's termination date draws near.

  3. May 27, 2021

    Illumina, Grail Say FTC Just Wants To Run Out Merger Clock

    Illumina and Grail have accused the Federal Trade Commission of plotting to resurrect its federal lawsuit challenging their proposed merger too close to a tie-up deadline for the companies to mount a proper defense, urging a California federal judge not to let the FTC drop the suit "without prejudice."

  4. May 20, 2021

    FTC To Focus On In-House Challenge Of Illumina Deal

    The Federal Trade Commission said Thursday enforcers plan to drop their bid for a court order to pause Illumina's planned $8 billion purchase of cancer testing company Grail and will instead focus on an administrative case challenging the tie-up.

  5. April 23, 2021

    FTC Calls In-House Ilumina Case As Important As Fed. Trial

    Federal Trade Commission staffers challenging Illumina's $8 billion plan to buy cancer testing company Grail are eager to get the case moving both in federal court and via the agency's in-house process, urging an administrative law judge Friday not to delay his part because of potential overlap.